ICCB280是一种有效的C/EBPα诱导剂。ICCB280通过激活C/EBPα并影响其下游靶点(例如C/EBPε，G-CSFR和c-Myc)，具有抗白血病特性，包括终末分化，增殖停滞和凋亡。
ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc)[1][2].
ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM[1].ICCB280 (10 μM; 2-8 d) increases the C/EBPα expression (mRNA and protein) and modulates its target genes in HL-60 cells[1].ICCB280 (10 μM; 7 d) induces granulocytic differentiation and subsequent apoptosis in HL-60 cells[1]. Cell Viability Assay[1] Cell Line: HL-60 cells
[1]. Radomska HS, et, al. A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen. 2015 Oct;20(9):1150-9. [2]. Sridhar R, et, al. Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα. Molecules. 2018 Aug 3;23(8):1938.
动态评分
0.0